Abstract
Neoadjuvant endocrine therapy (NET) is an attractive scenario to find novel biomarkers in oestrogen receptor-positive/HER2-negative breast cancer (ER+/HER2- BC). In this context, PAM50 multigene panel has been validated as a relapse predictor. This study aims to determine if PAM50-derived risk of recurrence (ROR) indexes at diagnosis correlate with biomarkers of response to NET.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
